Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
FDA clears new AI-enabled coronary plaque analysis software
Circle Cardiovascular Imaging, a Canadian medtech company, received the key approval for its cvi42 | Plaque platform.
A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025
The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.
Poor oral health tied to much higher risk of heart attack, stroke
Regularly going to the dentist, researchers added, may reduce cardiovascular risks by a significant margin.
PCI for eruptive calcified nodules: Drug-eluting stents, drug-coated balloons both linked to poor outcomes
In some cases, researchers noted, CABG may be a better treatment option. The group emphasized that alternative therapies are still needed to improve patient care.

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.

cvi42 | Plaque from Circle Cardiovascular Imaging

FDA clears new AI-enabled coronary plaque analysis software

Circle Cardiovascular Imaging, a Canadian medtech company, received the key approval for its cvi42 | Plaque platform.

Christian M. Spaulding, MD, PhD, at TCT 2025

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.

Poor oral health tied to much higher risk of heart attack, stroke

Regularly going to the dentist, researchers added, may reduce cardiovascular risks by a significant margin.

PCI for eruptive calcified nodules: Drug-eluting stents, drug-coated balloons both linked to poor outcomes

In some cases, researchers noted, CABG may be a better treatment option. The group emphasized that alternative therapies are still needed to improve patient care.

An Illinois appellate judge upheld a pervious trial victory that cleared and central Illinois cardiologist Amit Dande, MD, and Prairie Cardiovascular Consults LLP of alleged misdiagnosis of the severity of a patient's heart condition that led to his death prior to a schedule percutaneous coronary intervention (PCI).

Judge files lawsuit over husband’s death—alleges heart symptoms were mismanaged

The patient reported chest pain multiple times and had a family history of heart disease. According to the lawsuit, however, he was never referred to a cardiologist.

old woman or doctor shaking hands with patient

Most adults know nothing about CKM syndrome—but it impacts nearly everyone

Nearly 90% of adults are believed to already have at least one risk factor of CKM syndrome. The American Heart Association hopes patient education and physician collaborations can help increase awareness about this dangerous condition.

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes

Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.